Eli Lilly & Company LLYannounced that the FDA has approved the inclusion of additional data on the label of its psoriasis injection, Taltz. With the latest approval, Taltz label will now include data for psoriasis involving the genital area, which impacts roughly 63% of psoriasis patients over the course of their disease.
Eli Lilly Gets FDA Approval for Taltz in Genital Psoriasis
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться